[HTML][HTML] Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer
O Bragina, V Chernov, M Larkina, A Rybina… - Theranostics, 2023 - ncbi.nlm.nih.gov
The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is
of increasing importance with the recent approval of more efficacious HER2-targeted …
of increasing importance with the recent approval of more efficacious HER2-targeted …
The role of total-body PET in drug development and evaluation: status and outlook
X Meng, X Kong, L Xia, R Wu, H Zhu… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Total-body PET, an emerging technique, enables high-quality simultaneous total-body
dynamic PET acquisition and accurate kinetic analysis. It has the potential to facilitate the …
dynamic PET acquisition and accurate kinetic analysis. It has the potential to facilitate the …
Clinical implementation of total-body PET in China
Total-body (TB) PET/CT is a groundbreaking tool that has brought about a revolution in both
clinical application and scientific research. The transformative impact of TB PET/CT in the …
clinical application and scientific research. The transformative impact of TB PET/CT in the …
Comparison of an Affibody-based Molecular Probe and 18F-FDG for Detecting HER2-Positive Breast Cancer at PET/CT
X Guo, N Zhou, J Liu, J Ding, T Liu, G Song, H Zhu… - Radiology, 2024 - pubs.rsna.org
Background Human epidermal growth factor receptor 2 (HER2) affibody-based tracers could
be an alternative to nonspecific radiotracers for noninvasive detection of HER2 expression …
be an alternative to nonspecific radiotracers for noninvasive detection of HER2 expression …
Advances and challenges in immunoPET methodology
P Mohr, J van Sluis, MN Lub-de Hooge… - Frontiers in Nuclear …, 2024 - frontiersin.org
Immuno-positron emission tomography (immunoPET) enables imaging of specific targets
that play a role in targeted therapy and immunotherapy, such as antigens on cell …
that play a role in targeted therapy and immunotherapy, such as antigens on cell …
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
N Eissler, R Altena, A Alhuseinalkhudhur, O Bragina… - Biomedicines, 2024 - mdpi.com
Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule
Non-invasive assessment of fibrogenic activity, rather than fibrotic scars, could significantly
improve the management of fibrotic diseases and the development of anti-fibrotic drugs. This …
improve the management of fibrotic diseases and the development of anti-fibrotic drugs. This …
Current progress and future perspectives in total‐body positron emission tomography/computed tomography. Part II: Clinical applications
Total‐body positron emission tomography (TB‐PET) has significantly advanced from initial
conception to global commercial availability. The high sensitivity of TB‐PET has led to …
conception to global commercial availability. The high sensitivity of TB‐PET has led to …